Cargando…

Comment on: “Exploring the best treatment options for BRAF-mutant metastatic colon cancer”

Detalles Bibliográficos
Autores principales:	Milano, Gérard, Gal, Jocelyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250817/ https://www.ncbi.nlm.nih.gov/pubmed/32231291 http://dx.doi.org/10.1038/s41416-020-0819-5

Ejemplares similares

Exploring the best treatment options for BRAF-mutant metastatic colon cancer
por: Taieb, Julien, et al.
Publicado: (2019)

Comment on “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”
por: Uzunparmak, Burak, et al.
Publicado: (2018)

Reply to comment of “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”
por: Roseweir, Antonia K., et al.
Publicado: (2018)

Emerging treatment options for BRAF-mutant colorectal cancer
por: Ursem, Carling, et al.
Publicado: (2018)

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
por: Chen, Yungchang, et al.
Publicado: (2023)

Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice
por: Mangana, Joanna, et al.
Publicado: (2022)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

Comment on ‘Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study’
por: Dankner, Matthew, et al.
Publicado: (2018)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''
por: Shinozaki, Eiji, et al.
Publicado: (2018)

A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update
por: Thomopoulou, K., et al.
Publicado: (2019)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Adult colonic intussusception: Surgery still the best option
por: Dungerwalla, M, et al.
Publicado: (2012)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

Generation of patient-derived models from a metastatic pediatric diffuse leptomeningeal glioneuronal tumor with KIAA1549::BRAF fusion
por: Messiaen, Julie, et al.
Publicado: (2022)

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?
por: Bulbul, Ajaz, et al.
Publicado: (2018)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions
por: Donzelli, Sara, et al.
Publicado: (2022)

Erratum: Correction of Nomenclature of BRAF Mutation
por: Cho, Uiju, et al.
Publicado: (2014)

Clinical evaluation of hydration index using a corneometer in metastatic melanoma patients treated with BRAF/MEK inhibitors: a prospective study
por: Amabile, Simone, et al.
Publicado: (2022)

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options
por: Hummel, Michael, et al.
Publicado: (2021)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer
por: Lea, Andrew, et al.
Publicado: (2010)

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells()()
por: Kfir-Elirachman, Karin, et al.
Publicado: (2018)

How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
por: Hasegawa, Takahiro, et al.
Publicado: (2016)

A simple treatment option for Achilles tendinopathy?
por: Möst, Johannes
Publicado: (2018)

Good! Is it the best???
por: Selvarajan, Sandhiya, et al.
Publicado: (2013)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Comment on: Population preference for treatment of uncomplicated appendicitis
por: Patel, Rishi Rajesh, et al.
Publicado: (2022)

Comment on “Gastric cancer and family history”
por: Abadi, Amin Talebi Bezmin
Publicado: (2017)

Reply to “Good! is it the best ???
por: Chaturvedi, Aditi, et al.
Publicado: (2013)

The Best Way of Vaccinating
Publicado: (1896)

Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer
por: Altundag, Kadri
Publicado: (2022)

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3pp5at36a2sggv00jv580th7j1